Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes "CRESCENDO"

Terminated

Phase 3 Results N/A

Summary of Purpose

The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV... Trial Stopped: Company decision taken in light of demands by certain national health authorities

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 21 April 2016.

1 Dec 2005 6 Dec 2005 1 Apr 2009 1 Apr 2009 1 Apr 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions See All

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available